DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. PRCRP Research Highlights/News
  3. 2013 Peer Reviewed Cancer Research Program

NEWS RELEASE

Released: May 8, 2013

DEFENSE HEALTH PROGRAM
DEPARTMENT OF DEFENSE PEER REVIEWED CANCER RESEARCH PROGRAM
FUNDING OPPORTUNITIES FOR FISCAL YEAR 2013

The Fiscal Year 2013 (FY13) Defense Appropriation Act provides for $15 million to the Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP) to research cancers not addressed in breast, prostate, lung (excluding mesothelioma), and ovarian cancer research programs currently executed by the DoD U.S. Army Medical Research and Materiel Command (USAMRMC).

Congressionally Directed Topic Areas: To be considered for funding, applications for the FY13 PRCRP must address at least one of the Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted. The FY13 PRCRP Topic Areas are listed below:

  • Blood cancers
  • Colorectal cancer
  • Genetic cancer research
  • Kidney cancer
  • Listeria vaccine for cancer
  • Melanoma and other skin cancers
  • Mesothelioma
  • Neuroblastoma
  • Pancreatic cancer
  • Pediatric brain tumors

New for FY13 – Military Relevance Focus Areas:

  • Susceptibility to developing cancers due to exposure to militarily relevant environmental or chemical carcinogens (including transgenerational effects)
  • Identification of predictive and prognostic biomarkers of developing cancers due to exposure to militarily relevant environmental or chemical carcinogens
  • Molecular mechanisms by which environmental influences associated with military exposures alter gene structure, stability, and expression
  • Examination of cancer diagnosis and prognosis effects on the psychosocial well-being of military beneficiaries

The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY13 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2013. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Award Mechanism Eligibility Key Mechanism Elements Funding
Career Development Award Principal Investigator: Independent investigator at the level of Assistant Professor, Instructor, or equivalent within 7 years of first faculty appointment (or equivalent) at the time of application deadline

Designated Collaborator: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in at least one of the FY13 PRCRP Topic Areas. May not have a major research focus on breast, prostate, lung (excluding mesothelioma), or ovarian cancer
  • Supports early-career investigators to conduct innovative research in collaboration with an experienced cancer researcher
  • Must address at least one of the FY13 PRCRP Topic Areas
  • Strongly encouraged to address at least one of the FY13 PRCRP Military Relevance Focus Areas
  • Must not address breast, prostate, lung (excluding mesothelioma), or ovarian cancer research
  • Optional Nested Postdoctoral Fellow Traineeship
  • Preliminary data not required
  • Clinical trials not allowed
  • Maximum funding for the entire period of performance is $240,000 in direct costs (plus indirect costs)
  • If requesting the Optional Nested Postdoctoral Fellow Traineeship, the maximum funding for the entire period of performance is $360,000 in direct costs (plus indirect costs).
  • Maximum period of performance is 2 years
Idea Award with Special Focus Independent investigator at or above the level of Assistant Professor (or equivalent)
  • Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are directly relevant to service members, their families, and other military beneficiaries
  • Emphasis on innovation and military relevance/impact
  • Must address at least one of the FY13 PRCRP Topic Areas
  • Must address at least one of the FY13 PRCRP Military Relevance Focus Areas
  • Must not address breast, prostate, lung (excluding mesothelioma), or ovarian cancer research
  • Preliminary data discouraged
  • Clinical trials not allowed
  • Maximum funding for the entire period of performance is $300,000 in direct costs (plus indirect costs)
  • Maximum period of performance is 2 years

All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be made available on the Grants.gov website. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government's single entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements release may be sent to help@cdmrp.org. Email notifications of funding opportunities are sent as a courtesy and should not be used as a sole source of notification; applicants should monitor Grants.gov for official postings of funding opportunities.

For more information about the PRCRP or other CDMRP-sponsored programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs, 301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil